Patents by Inventor Robert McKay

Robert McKay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8076306
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: December 13, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, C. Frank Bennett, William A. Gaarde, Trisha Lockhart, Robert McKay
  • Patent number: 8017760
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: September 13, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madeline M. Butler, Robert McKay, Susan M. Freier, Kenneth W. Dobie
  • Publication number: 20110171730
    Abstract: The present invention provides methods of identifying oligomeric compounds, such as siRNA and double-stranded RNA compounds, having bioactivity in vivo, and kits.
    Type: Application
    Filed: December 21, 2010
    Publication date: July 14, 2011
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Robert McKay, Brett P. Monia, Brenda F. Baker, Namir Sioufi
  • Publication number: 20110136889
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: April 10, 2006
    Publication date: June 9, 2011
    Applicant: ISIS Pharmaceuticals Inc.
    Inventors: Sanjay Bhanot, Brett P. Monia, John Geisler, Robert Mckay, Kenneth W. Dobie
  • Publication number: 20110112171
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart diseaseby administration of antisense compounds targeted to PTPRU.
    Type: Application
    Filed: January 19, 2011
    Publication date: May 12, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
  • Patent number: 7919476
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: April 5, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lynnetta Watts, Robert McKay, Susan M. Freier
  • Publication number: 20110065775
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: September 15, 2010
    Publication date: March 17, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Patent number: 7897583
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: March 1, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
  • Patent number: 7884086
    Abstract: The present invention provides methods of identifying oligomeric compounds, such as siRNA and double-stranded RNA compounds, having bioactivity in vivo, and kits.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: February 8, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Robert McKay, Brett P. Monia, Brenda F. Baker, Namir Sioufi
  • Publication number: 20100311824
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box 01A are provided, in particular, for methods of treating diabetes.
    Type: Application
    Filed: August 20, 2010
    Publication date: December 9, 2010
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: KENNETH W. DOBIE, SANJAY BHANOT, ROBERT MCKAY, SANJAY K. PANDEY
  • Patent number: 7807649
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: October 5, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
  • Patent number: 7802655
    Abstract: A solid composition stick applicator is provided. The applicator comprises an applicator body having a first and second end, the second end having an opening through which a solid composition stick is dispensed. Within the applicator is housed a helical tension spring having a first spring end and a second spring end, the first spring end, second spring end, or both the first and second spring end held at a fixed position with respect to the applicator body. The helical tension spring is wound around a guide system that is housed within the applicator body. A pushing assembly is attached to the helical tension spring and the pushing assembly is movable from a first position at or near the first end of the applicator body, to a second position at or near the second end of the applicator body. Tension within the helical tension spring is greater in the first position than in the second position thereby urging the pushing assembly towards the second end of the applicator body.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: September 28, 2010
    Assignee: Kelsan Technologies Corp.
    Inventors: Jonathan de Wet, Ron C. Y. Hui, Douglas Robert McKay, Zdravko Zdjelar, Robert J. Harris
  • Publication number: 20100222412
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise antisense compounds, particularly antisense oligonucleotides which have particular in vivo properties, targeted to nucleic acids encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for treatment of diseases are provided.
    Type: Application
    Filed: January 14, 2010
    Publication date: September 2, 2010
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Robert McKay, Susan M. Freier, Sanjay Bhanot, Lynnetta Watts
  • Publication number: 20090326042
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: December 31, 2009
    Applicant: Isis Pharmaceuticals, Inc
    Inventors: Sanjay Bhanot, Richard Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewitz
  • Publication number: 20090325615
    Abstract: Methods, systems, and software for mediating SMS messages, and especially type 0 SMS messages, in a wireless mobile communications device configured to send and receive data using a GSM protocol and including a subscriber identity module (“SIM”) including electronic hardware and computer software executed by the hardware such that the SIM is configured to send, receive, and process messages using a Short Message System (“SMS”) between the wireless mobile communications device and a communications network. One aspect includes a method for mediating SMS messages comprising: configuring electronic hardware on the wireless mobile communications device to implement a firewall on the wireless mobile communications device, the firewall configured to identify and optionally mediate infrastructure SMS messages.
    Type: Application
    Filed: June 28, 2009
    Publication date: December 31, 2009
    Applicant: Oceans' Edge, Inc.
    Inventors: Robert McKay, Sam Emara, Steven Hildner, Thomas Shanley, Wesley Driver, Jay Lukin, Terry Bahr, Tim Berzins, Mihaela Mihaylova, Nathan Klonoski
  • Publication number: 20090326041
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: December 31, 2009
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20090318532
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: December 24, 2009
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20090306180
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: December 10, 2009
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert Mckay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20090306357
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: December 10, 2009
    Inventors: Sanjay Bhanot, Richard Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20090306179
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: December 10, 2009
    Applicant: ISIS Pharmaceuticals Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz